FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 21, 2022 USD ($)	Apr. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Inventories, net			$ 95,893		$ 95,893		$ 81,693
Raw materials			62,423		62,423		51,350
Finished goods			33,936		33,936		31,969
Research and development			7,657	$ 2,456	$ 17,096	$ 8,229
Useful life of intangible assets					8 years 10 months 24 days
Intangible asset impairment charge				$ 0	$ 112	$ 0
Acquired ANDA intangible assets
Finite-lived intangible gross carrying amount			$ 189,087		$ 189,087		$ 168,536
Useful life of intangible assets					8 years 3 months 18 days
Oakrum Pharma | Acquired ANDA intangible assets
Total asset purchase	$ 8,000
Finite-lived intangible gross carrying amount	7,200
Research and development	$ 1,200
Contingent liability not recognized, asset acquisition					$ 200
Useful life of intangible assets	7 years
Intangible asset impairment charge					0
Oakrum Pharma | Acquired ANDA intangible assets | Discount rate
Intangible asset measurement input	0.13
Sandoz
Total asset purchase		$ 20,700
Transaction costs		400
Finite-lived intangible gross carrying amount		11,400
Inventories, net		9,700
Raw materials		600
Sample inventory		1,000
Finished goods		$ 8,100
Useful life of intangible assets		7 years
Intangible asset impairment charge					$ 0
Sandoz | Discount rate
Intangible asset measurement input		0.10